MS drug safety in pregnancy under scrutiny: new study tracks birth outcomes
NCT ID NCT05688436
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observes over 1,100 pregnant women with multiple sclerosis to see if taking the drug diroximel fumarate (VUMERITY) affects their babies' health. Researchers will compare birth defects, miscarriages, preterm births, and stillbirths among women who took DRF, other MS drugs, or no MS drugs during pregnancy. No treatments are changed—only medical records are reviewed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OptumInsight
Eden Prairie, Minnesota, 55344-2503, United States